J. Mei

发表

Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial

Manish R. Patel, I. Flinn, R. Collins, 2015 .

Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

T. Miller, T. Kipps, J. Gabrilove, 2016, Haematologica.

Population Pharmacokinetics and Exposure Response Assessment of CC‐292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia

K. Takeshita, S. Zhou, M. Palmisano, 2017, Journal of clinical pharmacology.

Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program

Z. Cai, Jie Jin, J. Hou, 2016, BMC Cancer.

Continuous lenalidomide treatment for newly diagnosed multiple myeloma.

M. Beksac, M. Dimopoulos, W. Wiktor-Jedrzejczak, 2012, The New England journal of medicine.

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial

J. Gribben, L. Rassenti, T. Kipps, 2016, Blood Cancer Journal.

Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment

Z. Cai, Jie Jin, J. Hou, 2015, International Journal of Hematology.

Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*

J. Gribben, T. Kipps, M. Hallek, 2016, Leukemia & lymphoma.

A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma

M. Dimopoulos, R. Foà, M. Delforge, 2009 .

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone In Patients ≥ 65 Years with Newly Diagnosed Multiple Myeloma (NDMM): Continuous Use of Lenalidomide Vs Fixed-Duration Regimens

M. Dimopoulos, R. Hájek, M. Delforge, 2010 .

A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial

Z. Cai, Jie Jin, J. Hou, 2013, Journal of Hematology & Oncology.

Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)

J. Gribben, A. Chanan-Khan, T. Robak, 2017, Leukemia.

Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

T. Miller, T. Kipps, J. Gabrilove, 2013 .

Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial

M. Dimopoulos, A. Palumbo, R. Hájek, 2013, Haematologica.

Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial

M. Dimopoulos, R. Hájek, M. Delforge, 2013, Leukemia & lymphoma.

893 ATG-101, a novel PD-L1/4–1BB bispecific antibody, augments anti-tumor immunity through immune checkpoint inhibition and PDL1-directed 4–1BB activation

Yijing Ren, J. Mei, Bing Hou, 2021, Journal for ImmunoTherapy of Cancer.

Interim Results for the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CC-5013-CLL-009 Study)

T. Kipps, A. Chanan-Khan, S. Stilgenbauer, 2011 .

Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial

Hua Yang, E. Attar, S. Agresta, 2015 .

Preliminary Results from the Launch Study-a Multicenter, Open-Label Study of Selinexor, Dexamethasone and Chemotherapy Drugs in Relapsed/ Refractory Multiple Myeloma

Chun Zhang, Chunyan Sun, Jun-ying Li, 2022, Blood.

A phase 3 study to determine the efficacy and safety oflenalidomide combined with melphalan and prednisone in patients= 65 years with newly diagnosed multiple myeloma (NDMM)

M. Dimopoulos, A. Palumbo, R. Hájek, 2010 .

TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

L. Rassenti, T. Kipps, M. Hallek, 2013 .